Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Cameron Santoro is an associate editor for The Center for Biosimilars

Articles

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.  

Adalimumab Biosimilar GP2017 Shows Similar Safety, Efficacy to Originator in Patients With IBD 

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

Sarfaraz K. Niazi, PhD, comments on a poll he conducted revealing that many are still hesitant to remove clinical efficacy study requirements for biosimilars in his latest column.

BioRationality: Efficacy Testing and Interchangeability of Biosimilar Remains a Dogma for Most

On this episode, we discuss the abundance of oncology news from November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.

Biosimilar Oncology Roundup for November 2023—Podcast Edition

A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.

Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Regulation, Policy, and Litigation in Biosimilars

Videos

Biosimilar Interchangeability and Market Share

Interchangeability and Rheumatology Prescribing Practices

Biosimilars, Interchangeability, and Perceptions of Safety

Global Reference Products in Biosimilar Development

Inspection Reports and Proprietary Information

Reforms at the FDA Level

Biosimilars, Formularies, Contracting, and PBMs

Biosimilar Uptake and Health Plans

CMS and Blended Reimbursement Codes

Healthcare Reform Efforts and the BPCIA

State Laws and Biosimilar Substitution

The PTAB's Role in Biosimilar Patent Disputes

The Need for Clarity After <i>Sandoz v Amgen</i>

Upcoming Patent Litigation in Biosimilars

Challenges Ahead for Biosimilars